接下来，我们来概括一下整体盘面和应对策略。首先从板块效应来看，本周在指数没有大涨的背景下， 板块轮动速度较快，缺乏持续性上涨的板块，但板块机会呈现"雨露均沾"的状态。其中，半导体领域中 的光模块表现相对强势，主要原因是周初部分龙头公司发布了业绩增长明显的报告。此外，PCB柔性电 路板、银印制电路板也表现强势，代表了创新领域的科技半导体。在医药板块，创新药的局部品种有一 定表现，这些品种主要发布了临床批件或新品上市，表现较为活跃。不过，医药股整体表现并不突出， 近300家医药股中，一半业绩实现一季度增长，另一半业绩下滑，中报数据也未出现太多异动，因此整 体板块行情尚不明显。这些创新驱动的品种与前期下跌的传统行业形成对比，传统行业如光伏设备、电 池、钢铁、煤炭、有色等出现明显转折。这两方面合力使得市场转型效应明显增强。市场强弱与否，从 个人收益情况便可知晓。本周整体呈现回升状态，大部分中盘个股表现明显，大盘股因银行板块影响暂 时停滞，小盘股尾盘股表现相对较弱，中盘市值表现突出。 那么，接下来市场走势预期如何呢？我认为下周市场在反复震荡之后，大方向仍将向上。我一直强调， 看市场一定要关注政策和资金，这两点是市场的主 ...

报 告 摘 要 乘势而起：市场新高趋势追踪 触及新高的个股、行业和板块可被视为市场的风向标。越来越多的研究表明动量、趋势跟踪策略的有效性。本报告旨在定期跟踪市场中创新高的个股及其 分布，以追踪市场趋势、把握市场热点。 截至2025年7月18日，上证指数、深证成指、沪深300、中证500、中证1000、中证2000、创业板指、科创50指数250日新高距离分别为0.00%、 5.06%、4.64%、3.65%、0.91%、0.00%、10.71%、10.59%。中信一级行业指数中有色金属、钢铁、基础化工、通信、国防军工行业指数距离250日 新高较近，煤炭、食品饮料、房地产、消费者服务、交通运输行业指数距离250日新高较远。概念指数中，万得全A等权、区块链、金属非金属、可转债正 股、钢铁Ⅳ、万得双创、万得全A等概念指数距离250日新高较近。 见微知著：利用创新高个股进行市场监测 截至2025年7月18日，共1001只股票在过去20个交易日间创出250日新高。其中创新高个股数量最多的是医药、基础化工、机械行业，创新高个股数量占 比最高的是银行、综合金融、钢铁行业。按照板块分布来看，本周制造、周期板块创新高股票数量最多 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-042 上海美迪西生物医药股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持有的基本情况 截至本公告披露日，上海美迪西生物医药股份有限公司（以下简称"公司"） 股东林长青先生持有公司股份 5,473,654 股，占公司总股本的 4.07%，与其一致 行动人陈国兴先生合计持有公司股份10,348,808股，占公司总股本的 7.70%。 上述股份来源于公司 IPO 前取得的股份以及公司实施资本公积金转增股本， 林长青的股份已于 2022 年 11 月 7 日起解禁上市流通。 ? 减持计划的主要内容 因股东自身资金需求，公司股东林长青拟通过集中竞价或大宗交易的方式减 持合计不超过所持公司股票 2,000,000 股，即不超过公司总股本的 1.49%，自减 持计划披露之日起 15 个交易日后的 3 个月内（根据中国证监会及上海证券交易 所规定禁止减持的期间除外）实施。 上述股份减持价格按减持实施时的 ...

Group 1 - The bond market is experiencing a rise in credit bond issuance, with a total issuance of 13,687.12 billion yuan in June, an increase of 5,283.58 billion yuan from the previous month, and a net financing amount of 2,559.96 billion yuan, up by 2,055.38 billion yuan [39][40][51] - The manufacturing PMI for June is reported at 49.7, indicating a slight recovery, with the new orders index returning to the expansion zone at 50.2, suggesting improvements in consumer demand due to policy support [27][51] - The first batch of 10 science and technology innovation bond ETFs is set to launch on July 7, which is expected to enhance the attractiveness of high-rated innovation bonds and provide investment opportunities [8][10] Group 2 - The overall bond yield is expected to remain low due to a weak economic recovery, with the central bank maintaining a loose monetary policy and potential increases in fiscal spending [7][8][51] - The credit risk in the bond market remains manageable, with a rolling default rate of 0.28% in June, and only one new default subject reported [15][19] - The average issuance rates for various credit bonds show mixed trends, with short-term and medium-term bonds experiencing rate fluctuations, while the overall market remains favorable for issuers due to low financing costs [10][39][40]

科创板设立六年以来，凭借高度创新的市场机制及包容的融资环境，为中国科技创新企业提供了更为优良的发展平台。随着"科创板八条"、"1+6" 政策等陆 续推出，以及一揽子更具包容性和适应性的配套制度持续落地，优质科技型企业发展的难点堵点有望陆续疏通，科创板将为我国经济转型和新质生产力的发 展持续注入充足动能。 上海证券交易所与第一财经联合策划推出的《价值与投资》栏目，2025年第二期节目以"科创板六周年：资本助新，产业焕新"为主题，邀请科创板上市公司 董事长、上海交通大学教授、中证指数公司代表，详细解析资本助力下，科创企业持续发展壮大，并以科技创新为产业赋能的历程。 多方助力科创企业跨越成长周期 "正是有了科创板提供的种种金融支持，大大增强了企业的抗风险能力，博瑞医药得以在创新药研发方面持续快速推进。"袁建栋说。 在资本的有力支持下，博瑞医药六年累计研发投入达到12亿元，目前已有四条在研创新药管线，其中最重要的创新药物BGM0504注射液已进入III期临床， 公司正迎来创新药产品商业化前的关键时刻。 皓元医药董事长兼总经理郑保富介绍称，作为服务创新药产业链条的CRO企业，皓元医药成功登陆科创板后也迎来了快速发展的机 ...

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 0.19%, closing at 1007.53 points, with a total trading volume of 3.622 billion shares and a turnover of 124.775 billion yuan, resulting in an average turnover rate of 2.02% [1] - Among the tradable stocks on the STAR Market, 324 stocks closed higher, with 9 stocks experiencing a rise of over 10%, including Electric Wind Power, Fumiao Technology, and Shangwei New Materials, which hit the daily limit [1] - The distribution of turnover rates shows that 2 stocks had turnover rates exceeding 20%, 24 stocks had rates between 10% and 20%, and 59 stocks had rates between 5% and 10% [1] High Turnover Stocks - The stock with the highest turnover rate was Xinyuren, which closed up by 3.51% with a turnover rate of 23.24% and a transaction amount of 368 million yuan [3] - Other notable stocks included Aerospace Nanhu, which rose by 5.00% with a turnover rate of 20.06%, and Suochen Technology, which had a turnover rate of 19.66% [3] Sector Analysis - In terms of sector performance, the pharmaceutical and biotechnology sector had the most stocks with a turnover rate exceeding 5%, totaling 32 stocks, followed by the computer and electronics sectors with 18 and 7 stocks, respectively [2] - Among the high turnover stocks, 58 stocks rose today, with Fumiao Technology, Olin Biology, and DeMa Technology leading with increases of 20.02%, 18.93%, and 14.74%, respectively [2] Capital Flow - In terms of capital flow, 48 stocks with high turnover rates saw net inflows from main funds, with the highest net inflows recorded for Youkede, Kaiyin Technology, and Rongchang Biology, amounting to 104 million yuan, 9.403 million yuan, and 6.991 million yuan, respectively [2] - Conversely, the stocks with the largest net outflows included Guokexingong, Maiwei Biology, and Jiayuan Technology, with net outflows of 239 million yuan, 16.9 million yuan, and 13.4 million yuan, respectively [2] Leverage Fund Movements - A total of 51 stocks with high turnover rates recently received net purchases from leveraged funds, with notable increases in financing balances for Gaoce Shares, Shijia Photon, and Weixin Biology, which saw increases of 72.986 million yuan, 71.531 million yuan, and 71.373 million yuan, respectively [2]

资金流向方面，科创板百元股今日主力资金合计净流出1.29亿元，净流入资金居前的有拓荆科技、寒武 纪、恒玄科技等，净流入资金分别为4556.25万元、3631.48万元、3030.31万元；净流出资金居前的有海 光信息、百济神州、金山办公等，净流出资金分别为15785.72万元、6653.65万元、3030.46万元。 融资融券方面，百元股最新（7月17日）融资余额合计258.11亿元，融资余额居前的有寒武纪、海光信 息、中微公司等，最新融资余额分别为37.12亿元、32.60亿元、27.76亿元。最新融券余额合计为1.63亿 元，融券余额居前的有海光信息、寒武纪、惠泰医疗等，最新融券余额分别为0.17亿元、0.12亿元、 0.12亿元。 以最新收盘价计算，科创板平均股价为31.78元，其中股价超100元的有41只，股价最高的是寒武纪。 证券时报·数据宝统计显示，科创板股今日上涨的有324只，下跌的有257只，以收盘价为基准测算，科 创板平均股价为31.78元，其中，收盘价超过100元的有41只，股价在50元至100元之间的有121只，股价 在30元至50元的有167只。 科创板股中，收盘价最高的是寒武纪，今日 ...

以最新收盘价计算，A股平均股价为12.12元，其中股价超过100元的有96只。 市场表现方面，收盘股价超百元股中，今日平均上涨0.55%，跑赢沪指0.04个百分点。今日上涨的有48 只，涨幅居前的有深信服、汇成真空等，下跌的有47只，跌幅居前的有春风动力、源杰科技等。 | 688608 | 恒玄科技 | 232.80 | 1.06 | 0.02 | 电子 | | --- | --- | --- | --- | --- | --- | | 688692 | 达梦数据 | 228.30 | 2.81 | 0.03 | 计算机 | | 300760 | 迈瑞医疗 | 225.32 | 3.75 | 0.93 | 医药生物 | | 603129 | 春风动力 | 214.13 | -7.46 | 2.93 | 汽车 | | 688498 | 源杰科技 | 208.00 | -6.73 | 0.05 | 电子 | | 300779 | 惠城环保 | 205.52 | -0.60 | 3.13 | 环保 | | 688279 | 峰岹科技 | 203.26 | -0.73 | 0.02 | 电子 | | 688068 | ...

（原标题：揭秘涨停丨最高8连板，这些牛股获资金追捧） 今日（7月18日），A股市场收盘共52股涨停，剔除掉6只ST板块个股后，有46股涨停，21股封板未遂，整体封板率为71.23%。 涨停战场：上纬新材封单资金超9亿元 从收盘涨停板封单量来看，人民同泰封单量最高，有39.36万手；其次是上纬新材、美邦股份、中色股份、延华智能，涨停板封单分别为28.07万 手、22.24万手、22.09万手、18.11万手。 从连续涨停天数来看，上纬新材8连板，兰生股份6连板，*ST恒久5连板，天宸股份、海星股份、*ST威尔3连板，人民同泰、美邦股份、延华智能 等8股2连板，柳钢股份4日3板等。 以封单金额计算，13股封单资金超1亿元，上纬新材、美邦股份、人民同泰封单资金居前，分别为9.39亿元、5.19亿元、3.64亿元。 涨停个股：金圆股份、国机通用、久吾高科、盛新锂能 7月18日碳酸锂期货2509合约上涨2.82%，近20个交易日上涨17.42%。 金圆股份：公司捌千错盐湖提锂项目处于试生产阶段。 国机通用：公司开发研制出的三元锂电池材料过滤洗涤一体机，在多家锂电材料生产企业应用。 久吾高科：公司现有的盐湖提锂产品及技术 ...

Core Viewpoint - The article highlights the successful secondary listing of Kangzheng Pharmaceutical Holdings Limited on the Singapore Exchange, facilitated by China Galaxy Securities, marking a significant milestone for the company and reflecting the growing trend of Chinese enterprises seeking opportunities in Southeast Asia amid complex international market conditions [2][5][6]. Group 1: Market Context - The international capital market environment has become increasingly complex, with geopolitical and regulatory uncertainties posing significant challenges for some Chinese concept stocks [3]. - Southeast Asia has emerged as a preferred destination for Chinese enterprises to expand overseas, driven by strong economic growth, market potential, and geographical advantages [3]. - The strategic value of capital markets is becoming more pronounced as Chinese companies transition from "product export" to "industrial chain export," leading to increased demand for cross-border financing and M&A services [3]. Group 2: Kangzheng Pharmaceutical's Strategy - Kangzheng Pharmaceutical aims to leverage its secondary listing in Singapore as a strategic pivot to deepen its presence in Southeast Asia [4]. - The company has established differentiated advantages in various therapeutic areas, including cardiovascular, central nervous system, digestive, skin, and ophthalmology since its initial listing in Hong Kong in 2010 [4]. - The listing is viewed as a critical milestone in the company's history, intended to accelerate its internationalization strategy and enhance its global footprint [5]. Group 3: Role of China Galaxy Securities - China Galaxy Securities has played a pivotal role in facilitating the secondary listing of Kangzheng Pharmaceutical, showcasing its capabilities in navigating complex regulatory environments and providing tailored financial services [6][7]. - The firm has a significant local presence in Southeast Asia, with over 2,000 employees and more than 70 researchers, enabling it to understand market nuances and regulatory requirements effectively [7]. - The successful listing of Kangzheng Pharmaceutical follows the previous success of another company, Helen's, indicating a replicable and sustainable model for supporting Chinese enterprises in their international expansion [8]. Group 4: Broader Financial Services - China Galaxy Securities has extended its services beyond IPOs and the Singapore Exchange, successfully assisting various companies in cross-border financing, mergers, and acquisitions [9][10]. - The firm has facilitated significant projects for diverse industries, demonstrating its comprehensive service capabilities in addressing complex financial needs for both Chinese and Southeast Asian enterprises [10]. - As the internationalization of Chinese enterprises accelerates, China Galaxy Securities is positioned to continue playing a crucial role in connecting these companies with global opportunities [11].